ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Citizens Jmp Analyst Says

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its target price boosted by analysts at Citizens Jmp from $34.00 to $35.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s price target suggests a potential upside of 42.11% from the company’s previous close.

ACAD has been the topic of several other reports. Needham & Company LLC reissued a “buy” rating and issued a $34.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, January 5th. Wall Street Zen cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Wolfe Research assumed coverage on shares of ACADIA Pharmaceuticals in a research report on Monday. They set an “outperform” rating and a $33.00 price objective on the stock. Royal Bank Of Canada decreased their target price on shares of ACADIA Pharmaceuticals from $35.00 to $31.00 and set an “outperform” rating for the company in a report on Tuesday, February 3rd. Finally, Mizuho upgraded shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $29.00 to $35.00 in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $30.75.

ACADIA Pharmaceuticals Trading Down 1.4%

ACAD traded down $0.34 during midday trading on Thursday, reaching $24.63. The company’s stock had a trading volume of 335,376 shares, compared to its average volume of 1,389,944. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $28.35. The stock’s 50-day moving average is $25.62 and its 200-day moving average is $24.45. The firm has a market capitalization of $4.17 billion, a price-to-earnings ratio of 15.71, a PEG ratio of 8.63 and a beta of 0.66.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $1.48. ACADIA Pharmaceuticals had a net margin of 24.94% and a return on equity of 14.61%. The firm had revenue of $298.00 million during the quarter, compared to analyst estimates of $292.54 million. During the same period last year, the business earned $0.86 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. As a group, equities research analysts forecast that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $23.38, for a total value of $162,491.00. Following the completion of the sale, the executive vice president directly owned 7,609 shares in the company, valued at $177,898.42. The trade was a 47.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 26.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACAD. State Street Corp boosted its holdings in ACADIA Pharmaceuticals by 9.0% in the fourth quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company’s stock worth $211,296,000 after purchasing an additional 655,257 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company’s stock valued at $86,539,000 after buying an additional 106,807 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of ACADIA Pharmaceuticals by 4.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,920,974 shares of the biopharmaceutical company’s stock valued at $78,019,000 after buying an additional 122,840 shares during the period. First Trust Advisors LP boosted its stake in shares of ACADIA Pharmaceuticals by 2.8% in the 2nd quarter. First Trust Advisors LP now owns 2,434,376 shares of the biopharmaceutical company’s stock worth $52,509,000 after buying an additional 65,914 shares during the last quarter. Finally, Braidwell LP purchased a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter worth $50,760,000. Institutional investors own 96.71% of the company’s stock.

Trending Headlines about ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 results materially beat EPS expectations — reported $1.60 EPS vs. consensus ~$0.12 and roughly $298M in revenue (slight revenue beat) with YoY revenue growth and healthy margins; this is the main near-term catalyst. Read More.
• Positive Sentiment: Management set an ambitious FY‑2026 revenue target (up to about $1.28B) and highlighted continued commercialization of DAYBUE, STIX and NUPLAZID — signals of durable top-line growth if execution continues. Read More.
• Positive Sentiment: Analyst coverage turned bullish: Wolfe Research initiated with an “outperform” and a $33 price target, which reinforces upside expectations among institutional investors. Read More.
• Neutral Sentiment: Company published the full earnings release, slide deck and call transcript providing more color on commercial uptake and R&D priorities for investors to model future revenue and margin trends. Read More.
• Neutral Sentiment: Full Q4 earnings call transcript is available for deeper read of management’s commentary on DAYBUE prescriptions, NUPLAZID dynamics and pipeline timelines. Read More.
• Neutral Sentiment: Industry coverage/comparisons continue to surface (e.g., ACAD vs. Apellis) — useful for relative valuation context but not an immediate catalyst. Read More.
• Negative Sentiment: Policy/regulatory risk: mid‑size biotechs, including Acadia, face potential headwinds from proposals like MFN pricing pressure that could affect pricing and innovation economics if enacted. Read More.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.